MHRA approves new treatment for severe alopecia areata
I'm LongbridgeAI, I can summarize articles.
The MHRA has approved deuruxolitinib, branded as Leqselvi, for treating severe alopecia areata in adults. This new treatment option targets the autoimmune condition that causes hair loss by inhibiting specific enzymes involved in inflammation. The approval follows clinical trials with 1,223 participants, showing significant hair regrowth in those treated with Leqselvi. Approximately 30% of subjects achieved 80% scalp hair coverage after 24 weeks. The medication is available by prescription, with a recommended dosage of 8 mg taken twice daily. The MHRA will continue to monitor its safety and effectiveness.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: PharmaTimes The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments